Cover Image
市場調查報告書

鎮壓狀態 : 開發中產品分析

Sedation - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 253662
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
鎮壓狀態 : 開發中產品分析 Sedation - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 59 Pages
簡介

所謂鎮靜狀態是抑制興奮和不安狀態的狀態。症狀有講話緩慢、也會有舌頭打結口吃、無法集中、頭暈、呼吸和心跳減慢、血壓變低等。 佁療有使用巴比妥酸衍生物和苯二氮類衍生物。

本報告提供鎮壓狀態治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

鎮壓狀態概要

治療藥的開發

  • 開發中產品;概要

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • AstraZeneca PLC
  • Drawbridge Pharmaceuticals Pty Ltd
  • Jiangsu Nhwa Pharmaceutical Corporation Ltd.
  • NanoMedex Pharmaceuticals, Inc.
  • Paion AG
  • Primex Pharmaceuticals Oy
  • The Medicines Company
  • Therakind Limited

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8262IDB

Summary

Global Markets Direct's, 'Sedation - Pipeline Review, H2 2016', provides an overview of the Sedation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sedation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sedation and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sedation
  • The report reviews pipeline therapeutics for Sedation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sedation therapeutics and enlists all their major and minor projects
  • The report assesses Sedation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sedation

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sedation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sedation Overview
  • Therapeutics Development
    • Pipeline Products for Sedation - Overview
  • Sedation - Therapeutics under Development by Companies
  • Sedation - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Sedation - Products under Development by Companies
  • Sedation - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Drawbridge Pharmaceuticals Pty Ltd
    • Jiangsu Nhwa Pharmaceutical Corporation Ltd.
    • NanoMedex Pharmaceuticals, Inc.
    • Paion AG
    • Primex Pharmaceuticals Oy
    • The Medicines Company
    • Therakind Limited
  • Sedation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABP-700 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADV-6209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alphaxalone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • clonidine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EL-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol microemulsion - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remimazolam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GABA-A for Sedation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Sedation - Dormant Projects
  • Sedation - Discontinued Products
  • Sedation - Product Development Milestones
    • Featured News & Press Releases
      • Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
      • Apr 11, 2016: Paion Successfully Completes Patient Recruitment In Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy
      • Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
      • Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
      • Oct 14, 2015: Paion Receives Positive Feedback From Japanese Authority PMDA About Production Of Remimazolam For Japan
      • Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia
      • Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
      • May 04, 2015: Drawbridge Pharmaceuticals Moves Phaxan Forward
      • Mar 31, 2015: PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy
      • Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States
      • Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan
      • Oct 10, 2014: Paion Expects Ono'S Remimazolm Decision On Filing In Japan In November 2014
      • Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014
      • Aug 11, 2014: Diprivan (Propofol) Injectable Emulsion, USP Now Available in 10 mL Vials
      • Jul 21, 2014: Drawbridge Pharmaceuticals extends Phaxan patent portfolio with divisional patents granted for other neuroactive steroids
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Sedation, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Sedation - Pipeline by AstraZeneca Plc, H2 2016
  • Sedation - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2016
  • Sedation - Pipeline by Jiangsu Nhwa Pharmaceutical Corporation Ltd., H2 2016
  • Sedation - Pipeline by NanoMedex Pharmaceuticals, Inc., H2 2016
  • Sedation - Pipeline by Paion AG, H2 2016
  • Sedation - Pipeline by Primex Pharmaceuticals Oy, H2 2016
  • Sedation - Pipeline by The Medicines Company, H2 2016
  • Sedation - Pipeline by Therakind Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Sedation - Dormant Projects, H2 2016
  • Sedation - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Sedation, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top